Structural Genomics Consortium
Business Services · Canada · 207 Employees
View Company Info for Free
About
Headquarters
101 College St Ste 700, Toronto, Ontario, M5G 1...Phone Number
+44 1223944512Website
www.thesgc.orgRevenue
$16.3 MillionIndustry
Who is Structural Genomics Consortium
The Structural Genomics Consortium (SGC) is a global public private partnership dedicated to open science. It seeks to accelerate drug discovery by fostering collaboration among a large network of scientists in academia and industry and by making all research outputs, such as chemical probes, openly available to the scientific community. The current SGC research hubs are in Canada, Germany, Sweden, the United Kingdom, and the United States.Read more
Structural Genomics Consortium Org Chart
Is Structural Genomics Consortium your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Structural Genomics Consortium launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Structural Genomics Consortium had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Structural Genomics Consortium has new funding data
Earning: See what the market has to say on Structural Genomics Consortium recently announced quarterly report
Website visits: Recent activity has been detected on your website
Structural Genomics Consortium, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Structural Genomics Consortium is spiking on competitors!
Check if Structural Genomics Consortium has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Structural Genomics Consortium
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Similar Companies to Structural Genomics Consortium
Analyze insights from companies similar to Structural Genomics Consortium and make strategic comparisons based on performance, financial data, growth and unique benchmarks.
- Perimeter Institute93
$30.9M - ImmunoPrecise Antibodies65$14.7M
- Applied Biological Materials183$67.5M
- TransGen Biotech246$58.3M
- Gestion Promega Solutions143$36.8M
- Nexelis112<$5M
- SignalChem63$7.9M
- CEDARLANE88$37.7M
More similar companies
Structural Genomics Consortium Employee Growth Rate
View Structural Genomics Consortium’s full employee growth data
Percentage of growth
1st year Mask
2nd year Mask
Structural Genomics Consortium Tech Stack
Most Recent Scoops
Oct 20 2023
Event
Events
Structural Genomics Consortium News & Media
SGC and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
CHENGDU, China, Sept. 28, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a partnership with The Structural Genomics Consortium ("SGC"), a public-private partnership that supports the discovery of...
X-Chem and Structural Genomics Consortium Enter Into Collaboration to Unlock the Human Proteome and Promote Open Science
WALTHAM, Mass.--(BUSINESS WIRE)-- #DrugDiscovery--X-Chem and the Structural Genomics Consortium (SGC) have entered a collaboration aimed at creating new chemical tools to study human proteins.Cyclica and the Structural Genomics Consortium Co-crystallize DCAF1, a Key Component in Proteasomal Degradation, With a Novel Ligand to Support Targeted Therapeutics Discovery
TORONTO--(BUSINESS WIRE)-- #DCAF1--Cyclica, the partner of choice for data-driven drug discovery, and the Structural Genomics Consortium (SGC), a global public-private partnership dedicated to open science, have collaborated on a project in support of Target 2035, an initiative to discover probe molecules in support of developing medicines for all. As part of the initiative, the SGC and Cyclica examined three WDR proteins to discover small molecule binders using Cyclica’s proprietary deep learniXORTX Therapeutics Announces Appointment of Allan Williams and Paul Van Damme
CALGARY, Alberta, Jan. 29, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX), a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the appointment of Allan Williams and Paul Van Damme as directors of the Company and the resignation of Dr. Alan Moore as director. Dr. Alan Moore, a co-founder and a long time director of XORTX will remain with the Company as Senior Executive Consultant for
Read more news
Top Companies in Canada
Top 10 companies in Canada by revenue
Top 10 companies in Canada by number of employees
Top 10 companies in Canada by total funding amount
Frequently Asked Questions Regarding Structural Genomics Consortium
The Structural Genomics Consortium (SGC) is a global public private partnership dedicated to open science. It seeks to accelerate drug discovery by fostering collaboration among a large network of scientists in academia and industry and by making all research outputs, such as chemical probes, openly available to the scientific community. The curren... Read More
